德源药业:公司按照化学药品4类申报的非诺贝特胶囊收到国家药品监督管理局核准签发的药品注册证书,且视同通过一致性评价。该品种已纳入国家乙类医保用药目录(2024版)。国药现代:控股子公司国药集团致君(坪山)制药有限公司与安徽美来药业股份有限公司签署了《药品上市许可转让合同》,安徽美来将其产品乳果糖口服溶液(15ml:10g)上市许可转让予国药致君坪山,转让费总计人民币586万元。此次交易符合公司战略...
Source Link德源药业:公司按照化学药品4类申报的非诺贝特胶囊收到国家药品监督管理局核准签发的药品注册证书,且视同通过一致性评价。该品种已纳入国家乙类医保用药目录(2024版)。国药现代:控股子公司国药集团致君(坪山)制药有限公司与安徽美来药业股份有限公司签署了《药品上市许可转让合同》,安徽美来将其产品乳果糖口服溶液(15ml:10g)上市许可转让予国药致君坪山,转让费总计人民币586万元。此次交易符合公司战略...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.